A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2019
At a glance
- Drugs DCC 2618 (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Deciphera Pharmaceuticals
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 14 Sep 2018 Status changed from planning to not yet recruiting.
- 14 Nov 2017 According to a Deciphera Pharmaceuticals media release, company is planning to initiate the study in second half of 2018.